Molecular MRNA markers to detect and monitor circulating tumour cells in peripheral blood from urothelial carcinoma patients

Mercedes Marin-Aguilera; Lourdes Mengual; Moisés Burset; J. Rios; C. Gazquez; Elisabet Ars; M. J. Ribal; Humberto Villavicencio; A. Alcaraz

doi:10.1016/S1569-9056(09)60306-7

Molecular MRNA markers to detect and monitor circulating tumour cells in peripheral blood from urothelial carcinoma patients

Mercedes Marin-Aguilera, Lourdes Mengual, Moisés Burset, J. Rios, C. Gazquez, Elisabet Ars, M. J. Ribal, Humberto Villavicencio, A. Alcaraz

Departament de Pediatria, d’Obstetrícia i Ginecologia i de Medicina Preventiva i Salut Pública

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

Resum

Introduction & Objectives: Detecting haematogenous spread of bladder urothelial
carcinoma (BUC) still represents a major challenge in clinical practice. To test the
efficiency of six mRNA bladder markers in detecting and monitoring BUC haematogenous dissemination.
Material & Methods: Between 2002 and 2004, 317 peripheral blood (PB) samples were collected from 101 patients with BUC that underwent radical cystectomy and from 29 healthy controls. Sequential PB sampling was performed in patients at time of surgery and at 6, 12, 18 and 24 months afterwards. Median patients’ follow-up was 35 months. The presence of disseminated urothelial cells in PB was evaluated by measuring gene expression from pre-amplified (PA) cDNA of KRT20, FXYD3, C10orf116, UPK2, AGR2 and KRT19 genes, using quantitative RT-PCR (qRT-PCR). Gene expression data were correlated with patients’ follow-up and outcome.

Idioma original	Anglès
Pàgines (de-a)	196
Nombre de pàgines	196
Revista	European Urology, Supplements
DOIs	https://doi.org/10.1016/S1569-9056(09)60306-7
Estat de la publicació	Publicada - 2009

Accés al document

10.1016/S1569-9056(09)60306-7

Altres arxius i enllaços

https://publons.com/publon/45361279/

Com citar-ho

@article{7efbbb497de34585a30e825ad4b8862f,

title = "Molecular MRNA markers to detect and monitor circulating tumour cells in peripheral blood from urothelial carcinoma patients",

abstract = "Introduction & Objectives: Detecting haematogenous spread of bladder urothelialcarcinoma (BUC) still represents a major challenge in clinical practice. To test theefficiency of six mRNA bladder markers in detecting and monitoring BUC haematogenous dissemination. Material & Methods: Between 2002 and 2004, 317 peripheral blood (PB) samples were collected from 101 patients with BUC that underwent radical cystectomy and from 29 healthy controls. Sequential PB sampling was performed in patients at time of surgery and at 6, 12, 18 and 24 months afterwards. Median patients{\textquoteright} follow-up was 35 months. The presence of disseminated urothelial cells in PB was evaluated by measuring gene expression from pre-amplified (PA) cDNA of KRT20, FXYD3, C10orf116, UPK2, AGR2 and KRT19 genes, using quantitative RT-PCR (qRT-PCR). Gene expression data were correlated with patients{\textquoteright} follow-up and outcome.",

author = "Mercedes Marin-Aguilera and Lourdes Mengual and Mois{\'e}s Burset and J. Rios and C. Gazquez and Elisabet Ars and Ribal, {M. J.} and Humberto Villavicencio and A. Alcaraz",

year = "2009",

doi = "10.1016/S1569-9056(09)60306-7",

language = "English",

pages = "196",

}

TY - JOUR

T1 - Molecular MRNA markers to detect and monitor circulating tumour cells in peripheral blood from urothelial carcinoma patients

AU - Marin-Aguilera, Mercedes

AU - Mengual, Lourdes

AU - Burset, Moisés

AU - Rios, J.

AU - Gazquez, C.

AU - Ars, Elisabet

AU - Ribal, M. J.

AU - Villavicencio, Humberto

AU - Alcaraz, A.

PY - 2009

Y1 - 2009

N2 - Introduction & Objectives: Detecting haematogenous spread of bladder urothelialcarcinoma (BUC) still represents a major challenge in clinical practice. To test theefficiency of six mRNA bladder markers in detecting and monitoring BUC haematogenous dissemination. Material & Methods: Between 2002 and 2004, 317 peripheral blood (PB) samples were collected from 101 patients with BUC that underwent radical cystectomy and from 29 healthy controls. Sequential PB sampling was performed in patients at time of surgery and at 6, 12, 18 and 24 months afterwards. Median patients’ follow-up was 35 months. The presence of disseminated urothelial cells in PB was evaluated by measuring gene expression from pre-amplified (PA) cDNA of KRT20, FXYD3, C10orf116, UPK2, AGR2 and KRT19 genes, using quantitative RT-PCR (qRT-PCR). Gene expression data were correlated with patients’ follow-up and outcome.

AB - Introduction & Objectives: Detecting haematogenous spread of bladder urothelialcarcinoma (BUC) still represents a major challenge in clinical practice. To test theefficiency of six mRNA bladder markers in detecting and monitoring BUC haematogenous dissemination. Material & Methods: Between 2002 and 2004, 317 peripheral blood (PB) samples were collected from 101 patients with BUC that underwent radical cystectomy and from 29 healthy controls. Sequential PB sampling was performed in patients at time of surgery and at 6, 12, 18 and 24 months afterwards. Median patients’ follow-up was 35 months. The presence of disseminated urothelial cells in PB was evaluated by measuring gene expression from pre-amplified (PA) cDNA of KRT20, FXYD3, C10orf116, UPK2, AGR2 and KRT19 genes, using quantitative RT-PCR (qRT-PCR). Gene expression data were correlated with patients’ follow-up and outcome.

UR - https://publons.com/publon/45361279/

U2 - 10.1016/S1569-9056(09)60306-7

DO - 10.1016/S1569-9056(09)60306-7

M3 - Article

SN - 1569-9056

SP - 196

JO - European Urology, Supplements

JF - European Urology, Supplements

ER -

Molecular MRNA markers to detect and monitor circulating tumour cells in peripheral blood from urothelial carcinoma patients

Resum

Accés al document

Altres arxius i enllaços

Fingerprint

Com citar-ho